Trials / Not Yet Recruiting
Not Yet RecruitingNCT07493122
Study of IMC-S118AI in Type 1 Diabetes
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 154 (estimated)
- Sponsor
- Immunocore Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMC-S118AI | IMC-S118AI solution for infusion/injection |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2030-11-01
- Completion
- 2030-11-01
- First posted
- 2026-03-25
- Last updated
- 2026-03-25
Source: ClinicalTrials.gov record NCT07493122. Inclusion in this directory is not an endorsement.